Smac/DIABLO: A proapoptotic molecular target in renal cell cancer

Renal Cell Carcinoma: Molecular Targets and Clinical Applications

Volumn , Issue , 2009, Pages 335-346

  Mizutani, Yoichi ^a   Kawauchi, Akihiro ^a   Bonavida, Benjamin ^b   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cisplatin; Prognosis; RCC; Smac DIABLO; TRAI L; XIAP

Indexed keywords

EID: 77954152471     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-332-5_19     Document Type: Chapter

References (29)

1. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989;7:199-206.
2. Pantuck AJ, Zeng G, Belldegrun AS. Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-4652.
3. Delahunt B, Beckner RL, Bethwaite PB, Ribas JL. Computerized nuclear morphometry and survival in renal cell carcinoma: comparison with other prognostic indicators. Pathology 1994;26:353-360.
4. Van Der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendricks JC, Schalken JA. Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity. Cancer 1993;72:2667-2672.
5. Ruiz JL, Hernandez M, Martinez J, Vera C, Jimenez-Cruz JF. Value of morphometry as an independent prognostic factor in renal cell carcinoma. Eur Urol 1995;27:54-60.
6. Hofmockel G, Tsatalpas P, Muller H, Dammrich J, Poot M, Maurer-Schultze B. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 1995;76:296-301.
7. Cronin KJ, Williams NN, Kerin MJ, Creagh TA, Dervan PA, Smith JM. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J Urol 1994;152:834-839.
8. Rini BI, Vogelzang NJ. Prognostic factors in renal carcinoma. Semin Oncol 2000;27:213-220.
9. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic values of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-170.
10. Hofmockel G, Bassukas ID, Wittman A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol 1997;80:11-16.
11. Duensing S, Dallmann I, Grosse J, Buer J, Lopez Hannimen E, Deckert M. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 1994;51:309-315.
12. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994;7:766-771.
13. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 1997;80:1768-1773.
14. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 1995;2:156-161.
15. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995;46:27-32.
16. Mejean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol 2003;163:821-827.
17. Saelens X, Festjens N, Walle LV, Van Gurp M, Van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-2874.
18. Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol 2001;152:483-490.
19. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by elimination IAP inhibition. Cell 2000;102:33-42.
20. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
21. Fu J, Jin Y, Arend LJ. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem 2003;278:52660-52672.
22. Roberts DL, Merrison W, MacFarlane M, Cohen GM. The inhibitor of apoptosis proteinbinding domain of Smac is not essential for its proapoptotic activity. J Cell Biol 2001;153:221-228.
23. Mizutani Y, Nakanishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 2005;23:448-454.
24. Yoo NJ, Kim HS, Kim SY, Park CH, Jeon HM, Jung ES, Lee JY, Lee SH. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS 2003;111:382-388.
25. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, Finke JH. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 1999;59:2838-2842.
26. Gerhard MC, Zantl N, Weirich G, Schliep S, Seiffert B, Hacker G. Functional evaluation of the apoptosome in renal cell carcinoma. Br J Cancer 2003;89:2147-2154.
27. Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondriaderived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 2002;1:1051-1058.
28. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for APO2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-812.
29. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277:44236-44243.